100% Locally Owned, Independent and Free

100% Locally Owned, Independent and Free

Trial could be significant step forward in pursuit of new treatment for autoimmune disease

Do you have a news tip? Click here to send to our news team.

Annual NYE event navigates construction and road closures

The countdown to 2026 is officially on, and the Sunshine Coast is getting ready to farewell the year with fireworks, family-friendly celebrations and plenty More

With no campfire skills, Aussies playing with fire

Who doesn't enjoy a barbie or a get-together around the warmth of open flames, right? Yet with one in 10 bushfires caused by campfire negligence, More

Flood-affected groups bolstered by grants

A selection of not-for-profit groups impacted by wild weather on the greater Sunshine Coast have received state funding. The Nambour and Hinterland Australian Football Club, More

Photo of the day: farewell 2025

Photographer Maureen Brook took this photo of sand art at Coolum Beach, which is very fitting right now as we farewell 2025 and prepare More

Mum to pay off mortgage with festive lotto win

A Sunshine Coast woman is celebrating a miraculous festive season after winning almost $1 million. The Maroochydore mother won $936,000 in Saturday Gold Lotto draw More

Popular Thai eatery expands with second venue

A Thai restaurant that launched five years ago has expanded its footprint, opening a second venue at shopping and dining precinct. Known for its authentic More

A potential new treatment for rheumatoid arthritis will be tested on the Sunshine Coast.

The University of the Sunshine Coast Clinical Trials and Servatus Biopharmaceuticals Ltd are collaborating to trial a live biotherapeutic product, which is a field of medical therapy that is advancing globally.

Principal investigator Dr Peter de Wet said rheumatoid arthritis was an autoimmune disease that occurred when the immune system mistakenly attacked the body’s tissues, affecting the joints’ lining and causing joint pain and stiffness.

“Rheumatoid arthritis can be a debilitating condition that can impact many aspects of daily living,” he said via a UniSC media release.

“We are interested to learn about the role of the gut microbiome in treating symptoms of this condition.

“And while there are various strategies to improve joint mobility and muscle strength and reduce inflammation, some treatments are ineffective or have unwanted side effects, highlighting the need for new medicines to address the condition.”

He said the trial, to be held at UniSC’s newest clinic at Birtinya, represented a significant step forward in the pursuit of a new treatment.

Clinical Trials coordinator Jacinta Trevaskis.

Dr Samantha Coulson, head of clinical research at Servatus, said the live biotherapeutic product was an exciting and promising field of medical therapies that was advancing quickly on a global scale.

Servatus has isolated select microbial species, and pre-clinical investigations suggest the potential medication may be effective in treating autoimmune and inflammatory conditions.

“The gut microbiome plays such a vital role in many diseased states including rheumatoid arthritis, as the gut bacteria and immune system have a bidirectional influence on each other,” Dr Coulson said.

By using well-defined bacterial strains, we hope to regulate the hyperactive immune response seen in rheumatoid arthritis with significantly less side effects as with many of the current drugs in the market.

The product that could make a difference.

The team is seeking participants aged between 18 and 80 with confirmed rheumatoid arthritis and who are experiencing daily joint pain and stiffness.

Participants will need to commit to up to six visits at the Birtinya clinic over about four months and they will be reimbursed for their time on the trial.

Those interested in volunteering can find more information at UniSC Clinical Trials.

Local journalists supporting local people. Help keep independent and fair Sunshine Coast news coming by subscribing to our FREE daily news feed. All it requires is your name and email at the bottom of this article.

Subscribe to SCN’s free daily news email

This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
[scn_go_back_button] Return Home
Share